← All trials
NCT04905563
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 7, 2021
- Primary completion
- May 21, 2025
- Completion date
- May 21, 2026
- First posted
- May 27, 2021
- Last posted
- Sep 13, 2021
- Enrollment
- 150
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of TennesseeLead sponsor
- University of TennesseeReponsible party - principal investigator
- University of TennesseeOverall official - principal investigator
- The Campbell FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.